erlotinib hydrochloride has been researched along with elisidepsin in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (elisidepsin) | Trials (elisidepsin) | Recent Studies (post-2010) (elisidepsin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 21 | 5 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aracil, M; Jimeno, J; Ling, YH; Perez-Soler, R; Zou, Y | 1 |
| Coronado, C; Dios, JL; Fernández-García, EM; Goel, S; Miguel-Lillo, B; Morán, T; Rosell, R; Viteri, S | 1 |
1 trial(s) available for erlotinib hydrochloride and elisidepsin
| Article | Year |
|---|---|
Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Depsipeptides; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2016 |
1 other study(ies) available for erlotinib hydrochloride and elisidepsin
| Article | Year |
|---|---|
Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Survival; Depsipeptides; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |